Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Azenta, Inc. will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live ...

Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the ...

High Blood Pressure has become a major public health concern in recent times. Research into natural remedies for health ...

According to our calculations, a $1000 investment made in January 2015 would be worth $4,020.91, or a gain of 302.09%, as of January 27, 2025, and this return excludes dividends but includes price ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated between 2025 and 2034. As industries undergo transformation and consumer ...